Home/Pipeline/Alzheimer's Tau Biomarker SMAs (p-tau, BD-tau)

Alzheimer's Tau Biomarker SMAs (p-tau, BD-tau)

Alzheimer's Disease

Research/CommercialActive in RUO/Partner Assays

Key Facts

Indication
Alzheimer's Disease
Phase
Research/Commercial
Status
Active in RUO/Partner Assays
Company

About Bioventix

Bioventix is a specialist biotechnology company focused on the development and supply of high-affinity sheep monoclonal antibodies for the global in-vitro diagnostics (IVD) industry. Founded in 2004 and listed on the London AIM market, its core strategy is to identify diagnostic assays with unmet needs for better antibodies, develop superior SMAs, and license them to major diagnostic partners, generating stable, high-margin royalty revenue. The company has achieved consistent profitability and growth by leveraging its unique technological niche to become a critical, behind-the-scenes supplier to nearly all major global immunodiagnostics companies.

View full company profile

Other Alzheimer's Disease Drugs

DrugCompanyPhase
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
LecanemabBioArcticLaunched
BAN2401BioArcticPreclinical
Undisclosed ProgramsJohnson and Johnson Innovative MedicinePipeline
MK-6240 (florquinitau)Lantheus Medical ImagingRegulatory Filing
NAV-4694 (flutafuranol)Lantheus Medical ImagingPhase 3
LNTH-2620/PI-2620Lantheus Medical ImagingPhase 3
itMSCsStemedica Cell TechnologiesClinical Development
PMN310ProMIS NeurosciencesPhase 1b